Estradiol + noretysteron i Etonogestrel + etynyloestradiol: interakcja

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known.

Exacerbation of Other Conditions Estrogen therapy, including Estradiol/Norethindrone Acetate Tablets, may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas.

…incidence for new users of Etonogestrel/Ethinyl Estradiol Vaginal Ring to be 11.4 events per 10,000 WY, for new users of a levonorgestrel (LNG)-containing COC 9.2 events per 10,000 WY, and for users of other COCs available during the course of the study Includes low-dose COCs containing the following progestins: norgestimate, norethindrone, or levonorgestrel.

…low-dose COCs containing the following progestins: chlormadinone acetate, cyproterone acetate, desogestrel, dienogest, drospirenone, ethynodiol diacetate, gestodene, levonorgestrel, norethindrone, norgestimate, or norgestrel HR Adjusted for age, BMI, duration of use, VTE history : 0.8 (0.5-1.5) COCs available excluding DSG- or GSD -containing OCs HR : 0.8 (0.4-1.7)…

Effects of CHCs on Other Drugs CHCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations.

The effects of other antibiotics on etonogestrel or ethinyl estradiol concentrations have not been evaluated.